The Antimicrobial Peptide, Dermaseptin DMS-DA6, a Promising Alternative to Conventional Antibiotic in the Treatment of N. brasiliensis-Induced Actinomycetoma.

Authors

Diana Ivonne Duarte-Mata, Anna Velia Vázquez-Marmolejo, Estefania Alemán-Navarro, Christophe Piesse, Yvonne Rosenstein, Constance Auvynet, Mario Cesar Salinas-Carmona

Published in

Probiotics and antimicrobial proteins. Jul 21, 2026. Epub Jul 21, 2026.

Abstract

Actinomycetoma is a chronic infectious disease recognized by the World Health Organization as a neglected tropical disease. In the Americas, the most common etiologic agent is the Gram-positive bacterium, Nocardia brasiliensis. This pathogen is a facultative intracellular organism that can multiply and survive within macrophages, evading microbicidal mechanisms by inducing an immunosuppressive environment. Current antibiotic treatments are expensive, prolonged and toxic, and bacterial resistance has been reported. Host defense peptides, known for their bactericidal and immunomodulatory properties, represent a promising new therapeutic approach. Recently, DMS-DA6, a dermaseptin isolated from the Mexican tree frog, Pachymedusa dacnicolor, has been shown to exert strong activity against Gram-positive bacteria, including multidrug-resistant strains. Our study evaluated the effects of DMS-DA6 in a mouse model of actinomycetoma caused by N. brasiliensis, comparing it with the conventional antibiotic linezolid. Infected mice were treated either twice a week with this peptide at a dose of 12.5 mg/kg or every 12 h with linezolid at a dose of 25 mg/kg over a four-week period. Our results suggest that DMS-DA6 is more effective at resolving the disease than linezolid, as it achieves a similar reduction in inflammation and bacterial load of the footpad at a lower dose and with fewer injections. Furthermore, DMS-DA6 modulates IL-10, IL-1α, and IL-6 levels at the chronic stage of actinomycetoma infection and increases the abundance of CD4 + and CD8 + T lymphocytes in the infected footpad. These findings highlight the potential of DMS-DA6 as an innovative addition to current treatments.

PMID:
42479333
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.